{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:01:37Z","timestamp":1777953697311,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd012336","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000}}],"reference-count":124,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012336.pub2","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:52:11Z","timestamp":1613004731000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction"],"prefix":"10.1002","volume":"2021","author":[{"given":"Ran","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Urology; Guang An Men Hospital, China Academy of Chinese Medical Sciences; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Internal Medicine & Outpatients Management Office; Guang An Men Hospital, China Academy of Chinese Medical Sciences; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangling","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension; Mayo Clinic; Rochester Minnesota USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"China Academy of Chinese Medical Sciences; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Lai","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Urology; Guang An Men Hospital, China Academy of Chinese Medical Sciences; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Urology; Guang An Men Hospital, China Academy of Chinese Medical Sciences; Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology; Yonsei University Wonju College of Medicine; Wonju Korea, South"},{"name":"Center of Evidence Based Medicine, Institute of Convergence Science; Yonsei University; Seoul Korea, South"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"issue":"24","key":"10.1002\/14651858.CD012336.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.4103\/0366-6999.195461","article-title":"Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial","volume":"129","author":"Cai","year":"2016","journal-title":"Chinese Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"e933","DOI":"10.1016\/S1569-9056(17)30597-3","article-title":"A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms\/benign prostatic hyperplasia and storage symptoms","volume":"16","author":"Cho","year":"2017","journal-title":"European Urology, Supplements"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e12938","DOI":"10.1111\/ijcp.12938","article-title":"A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms\/benign prostatic hyperplasia and storage symptoms","volume":"71","author":"Cho","year":"2017","journal-title":"International Journal of Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD012336.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"806","DOI":"10.14053\/j.cnki.ppcr.2012.12.029","article-title":"Combination of tamsulosin and solifenacin treatment for benign prostatic hyperplasia with overactive bladder","volume":"15","author":"He","year":"2012","journal-title":"Practical Pharmacy and Clinical Remedies"},{"issue":"11","key":"10.1002\/14651858.CD012336.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.4111\/kju.2009.50.11.1078","article-title":"The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms","volume":"50","author":"Kang","year":"2009","journal-title":"Korean Journal of Urology"},{"issue":"9","key":"10.1002\/14651858.CD012336.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU international"},{"issue":"19","key":"10.1002\/14651858.CD012336.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"Journal of the American Medical Association"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","article-title":"Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size","volume":"55","author":"Roehrborn","year":"2009","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.eururo.2012.07.003","article-title":"Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial","volume":"63","author":"Kaplan","year":"2013","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/pcan.2011.22","article-title":"Initial combined treatment with anticholinergics and \u03b1-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study","volume":"14","author":"Lee","year":"2011","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/luts.12124","article-title":"Initial use of high-dose anticholinergics combined with alpha-blockers for male lower urinary tract symptoms with overactive bladder: a prospective, randomized preliminary study","volume":"9","author":"Lee","year":"2016","journal-title":"Lower Urinary Tract Symptoms"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.11699\/cyxb20130326","article-title":"Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder","volume":"38","author":"Liu","year":"2013","journal-title":"Journal of Chongqing Medical University"},{"issue":"9","key":"10.1002\/14651858.CD012336.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.4065\/83.9.1002.","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0015|cit15","first-page":"e465","article-title":"Long term efficacy of a combination therapy with an anticholinergic agent and an \u03b11-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study","volume":"195","author":"Matsukawa","year":"2016","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"e867+e867a","DOI":"10.1016\/S1569-9056(16)60869-2","article-title":"Long term efficacy of a combination therapy with an anticholinergic agent and an \u03b11-blocker for patients with benign prostatic enlargement complicated by overactive bladder: a randomized, prospective, comparative trial using a urodynamic study","volume":"15","author":"Matsukawa","year":"2016","journal-title":"European Urology, Supplements"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/nau.23013","article-title":"Long-term efficacy of a combination therapy with an anticholinergic agent and an \u03b11-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study","volume":"36","author":"Matsukawa","year":"2016","journal-title":"Neurourology and Urodynamics"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0018|cit18","unstructured":"Memon I Abdullah A Pirzada A Javed A Sheikh S Agha G Efficacy of alfuzosin with or without tolterodine, in men with benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms: a randomized controlled trial Urology 2013 82 3 Suppl 1 S78"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0019|cit19","first-page":"421","article-title":"Efficacy of alfuzosin with or without tolterodine, in benign prostatic hyperplasia (BPH) having irritative (overactive bladder) symptoms","volume":"39","author":"Memon","year":"2014","journal-title":"Rawal Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1757-5672.2010.00081.x","article-title":"Randomized controlled trial to treat benign prostatic hyperplasia with overactive bladder using an alpha-blocker combined with anticholinergics","volume":"3","author":"Nishizawa","year":"2011","journal-title":"Lower Urinary Tract Symptoms"},{"issue":"8","key":"10.1002\/14651858.CD012336.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/iju.13721","article-title":"Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: results from a randomized pilot study","volume":"25","author":"Sakalis","year":"2018","journal-title":"International Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1590\/S1677-5538.IBJU.2013.04.09","article-title":"Efficacy and safety of propiverine and terazosin combination for one year in male patients with LUTS and detrusor overactivity","volume":"39","author":"Sener","year":"2013","journal-title":"International Brazilian Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3969\/j.issn.1674-8115.2011.06.028","article-title":"Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia","volume":"31","author":"Shen","year":"2011","journal-title":"Journal of Shanghai Jiaotong University (Medical Science)"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD012336.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.urology.2011.07.099","article-title":"Evaluating the efficacy and safety of fixed-dose combinations of tamsulosin OCAS and solifenacin in male LUTS with storage and voiding symptoms: an overview of the NEPTUNE trial","volume":"78","author":"Drake","year":"2011","journal-title":"Urology"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/j.urology.2011.07.832","article-title":"Safety of tamsulosin OCAS\u2122 plus solifenacin in men with LUTS associated with BPH in the SATURN trial","volume":"78","author":"Haab","year":"2011","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Kerrebroeck P Krhut J Liehne J Gomberg V Cambronero Santos J Garcia-Hernandez A The effects of tamsulosin OCASplus solifenacin on quality of life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial Urology 2011 78 3 Suppl 1 S58 s59","DOI":"10.1016\/j.urology.2011.07.101"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Kerrebroeck PE Oelke M Katona F Krhut J Liehne J Gomberg V Effects of tamsulosin OCAS and solifenacin on efficacy and QoL parameters in men with LUTS\/BPH in the SATURN trial (Abstract number 327) European Urology, Supplements 2011 10 2 120 10.1016\/S1569-9056(11)60323-0","DOI":"10.1016\/S1569-9056(11)60323-0"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","article-title":"Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.urology.2011.07.101","article-title":"The effects of tamsulosin OCAS\u2122 plus solifenacin on Quality of Life (QoL) parameters in men with LUTS associated with BPH participating in the SATURN trial","volume":"78","author":"Van Kerrebroeck","year":"2011","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.urology.2010.07.354","article-title":"Efficacy of tamsulosin OCAS\u2122 plus solifenacin (TOCAS+Soli) in male LUTS: results from a randomized, dose-ranging, phase II trial (SATURN)","volume":"76","author":"Van Kerrebroeck","year":"2010","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1569-9056(11)60323-0","article-title":"Effects of tamsulosin OCAS\u2122 and solifenacin on efficacy and QoL parameters in men with LUTS\/BPH in the SATURN trial","volume":"10","author":"Van Kerrebroeck","year":"2011","journal-title":"European Urology, Supplements"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Wyndaele J Cicalese AR Jzerman WI Sokol R Hechelmann W Garcia-Hernandez A Combination therapy with tamsulosin OCAS and solifenacin is more effective than solifenacin monotherapy as a treatment for male LUTS associated with BPH: results from the SATURN trial Urology 2011 78 3 Suppl 1 S58","DOI":"10.1016\/j.urology.2011.07.100"},{"issue":"34","key":"10.1002\/14651858.CD012336.pub2-BIB0034|cit34","first-page":"27","article-title":"Efficacy of large doses of tamsulosin combined with fesoterodine fumarate in treatment of benign prostatic hyperplasia with overactive bladder","volume":"25","author":"Wang","year":"2015","journal-title":"China Journal of Modern Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.12669\/pjms.334.12757","article-title":"Tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder","volume":"33","author":"Wang","year":"2017","journal-title":"Pakistan Journal of Medical Sciences"},{"issue":"7","key":"10.1002\/14651858.CD012336.pub2-BIB0036|cit36","first-page":"639","article-title":"Combination of tolterodine and tamsulosin for benign prostatic hyperplasia","volume":"15","author":"Wu","year":"2009","journal-title":"Zhonghua Nan Ke Xue [National Journal of Andrology]"},{"issue":"12","key":"10.1002\/14651858.CD012336.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.16252\/j.cnki.issn1004-0501-2010.12.036","article-title":"Doxazosin combined with tolterodine tartrate in the treatment of benign prostatic hyperplasia with overactive bladder","volume":"31","author":"Yu","year":"2010","journal-title":"Sichuan Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0038|cit38","first-page":"539","article-title":"Prospective comparison of two treatment modalities in benign prostatic hyperplasia: alpha-blocker alone vs. alpha-blocker plus anticholinergic combination","volume":"30","author":"Aldemir","year":"2010","journal-title":"Turkiye Klinikleri Tip Bilimleri Dergisi"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"650","DOI":"10.26452\/ijrps.v11i1.1871","article-title":"Role of trospium chloride and tamsulosin therapy for treating patients with symptoms of over-active bladder related to benign prostatic enlargement","volume":"11","author":"Ali","year":"2020","journal-title":"International Journal of Research in Pharmaceutical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD012336.pub2-BIB0040|cit40","first-page":"13820","article-title":"Therapeutic effect of solifenacin combined with tamsulosin on benign prostatic hyperplasia with overactive bladder","volume":"11","author":"Chen","year":"2018","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0041|cit41","first-page":"7","article-title":"Effect of anti-cholinergics with tamsulosin for treating benign prostate hyperplasia patients with an overactive bladder: a clinico-comparative study","volume":"6","author":"Deva","year":"2017","journal-title":"International Journal of Medical Research & Health Sciences"},{"issue":"07","key":"10.1002\/14651858.CD012336.pub2-BIB0042|cit42","first-page":"909","article-title":"Efficacy of high dose tamsulosin plus fumaric acid fesoterodine for benign prostatic hyperplasia and the importance of high quality of nursing care","volume":"15","author":"Du","year":"2015","journal-title":"Evaluation and analysis of drug-use in hospitals of China"},{"issue":"04","key":"10.1002\/14651858.CD012336.pub2-BIB0043|cit43","first-page":"84","article-title":"Tamsulosin treatment tolterodine combined detrusor instability prostatic hyperplasia","volume":"50","author":"Fang","year":"2012","journal-title":"China Modern Doctor"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0044|cit44","unstructured":"Fujihara A Ukimura O Iwata T Ushijima S Toiyama D Suzuki K Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder Neurourology and Urodynamics 2010 21 S152 s154"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"348","DOI":"10.13263\/j.cnki.nja.2011.04.019","article-title":"Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity","volume":"17","author":"Gan","year":"2011","journal-title":"Zhonghua Nan Ke Xue [National Journal of Andrology]"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.13263\/J.CNKI.NJA.2014.03.009","article-title":"Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder","volume":"20","author":"Gao","year":"2014","journal-title":"Zhonghua Nan Ke Xue [National Journal of Andrology]"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3969\/j.issn.1006-4931.2019.06.016","article-title":"Clinicals study on tolterodine combined with tamsulosin in the treatment of prostatic hyperplasia complicated with overactive bladder","volume":"28","author":"He","year":"2019","journal-title":"China Pharmaceuticals"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13685538.2017.1398723","article-title":"Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage","volume":"21","author":"Kosilov","year":"2018","journal-title":"Aging Male"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11255-013-0551-7","article-title":"Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study","volume":"46","author":"Lee","year":"2014","journal-title":"International Urology and Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.5336\/medsci.2012-28431","article-title":"Additive role of trospium chloride in the management of men with voiding and storage symptoms","volume":"32","author":"Malko\u00e7","year":"2012","journal-title":"Turkiye Klinikleri Journal of Medical Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.urology.2011.07.1289","article-title":"Role of the addition of trospium chloride to the treatment of patients with both low urinary tract symptoms and overactive bladder","volume":"78","author":"Malkoc","year":"2011","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Maruyama O Kawachi Y Hanazawa K Koizumi K Yamashita R Sugimura S Naftopidil monotherapy versus naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study International Journal of Urology 2006 13 10 1280 5 10.1111\/j.1442-2042.2006.01538.x","DOI":"10.1111\/j.1442-2042.2006.01538.x"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0053|cit53","unstructured":"Clinical trial to compare the solifenacin\/tamsulosin combination therapy with tamsulosin monotherapy for LUTS due to BPH clinicaltrials.gov\/show\/NCT02972268"},{"issue":"10","key":"10.1002\/14651858.CD012336.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1671-945X.2019.10.002","article-title":"Analysis of efficacy and safety of combination therapy of doxazosin and solifenacin for benign prostatic hyperplasia with overactive bladder","volume":"17","author":"Qin","year":"2019","journal-title":"Journal of China Prescription Drug"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.juro.2008.05.050","article-title":"Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms","volume":"180","author":"Rovner","year":"2008","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0056|cit56","first-page":"S79","article-title":"Combination of solifenacin with tamsulosin but not tamsulosin affects morphometric and functional parameters of the prostate in patients with benign prostate enlargement (BPE) and overactive bladder (OAB). results from a randomized pilot study","volume":"35","author":"Sakalis","year":"2016","journal-title":"Neurourology and Urodynamics"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/j.juro.2013.02.2743","article-title":"The combination therapy of imidafenacin and tamsulosin is effective and safe in benign prostatic hyperplasia patients with overactive bladder; the one year results from addition study","volume":"189","author":"Takahashi","year":"2013","journal-title":"Journal of Urology"},{"issue":"28","key":"10.1002\/14651858.CD012336.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3969\/j.issn.1009-4393.2013.28.102","article-title":"Clinical analysis of tamsulosin combined with solifenacin in the treatment of benign prostatic hyperplasia","volume":"19","author":"Wang","year":"2013","journal-title":"Contemporary Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012336.pub2-BIB0059|cit59","first-page":"4293","article-title":"Efficacy of tamsulosin combined with solifenacin in the treatment of different symptoms of benign prostatic hyperplasia combined with overactive bladder","volume":"36","author":"Xin","year":"2016","journal-title":"Chinese Journal of Gerontology"},{"issue":"07","key":"10.1002\/14651858.CD012336.pub2-BIB0060|cit60","first-page":"129","article-title":"The difference in efficacy and safety of tamsulosin combined with solifenacin and tamsulosin alone in improving lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"12","author":"Xu","year":"2015","journal-title":"Northern Pharmacy"},{"issue":"09","key":"10.1002\/14651858.CD012336.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.14009\/j.issn.1672-2124.2018.09.016","article-title":"Efficacy and safety of tamsulosin combined with solifenacin in treatment of mild and moderate benign prostatic hyperplasia with overactive bladder","volume":"18","author":"Yan","year":"2018","journal-title":"Evaluation and Analysis of Drug-Use in Hospitals of China"},{"issue":"22","key":"10.1002\/14651858.CD012336.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.16659\/j.cnki.1672-5654.2014.22.078","article-title":"The observation of the effect of tamsulosin joint tolterodine in the treatment of the instability of prostatic hyperplasia and bladder detrusor","volume":"12","author":"Yang","year":"2014","journal-title":"China Health Industry"},{"issue":"01","key":"10.1002\/14651858.CD012336.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.13263\/j.cnki.nja.2011.01.020","article-title":"M-blockers combined with alpha blockers in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a randomized controlled trial","volume":"17","author":"Zhao","year":"2011","journal-title":"National Journal of Andrology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourology and Urodynamics"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD012336.pub2-BIB0065|cit65","first-page":"S93","article-title":"Evaluation and treatment of lower urinary tract symptoms in older men","volume":"189","author":"Abrams","year":"2013","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0067|cit67","unstructured":"American Urological Association Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (2018) www.auanet.org\/guidelines\/benign-prostatic-hyperplasia\/lower-urinary-tract-symptoms-(2018)"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0022-5347(17)49698-4","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.105.094961","article-title":"M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder","volume":"316","author":"Braverman","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1464-410X.2004.05022.x","article-title":"Pharmacological therapy of benign prostatic hyperplasia\/lower urinary tract symptoms: an overview for the practising clinician","volume":"94","author":"Chapple","year":"2004","journal-title":"BJU International"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"European Urology"},{"issue":"5-6","key":"10.1002\/14651858.CD012336.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2680.2001.00231.x","article-title":"The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro","volume":"21","author":"Chess-Williams","year":"2001","journal-title":"Journal of Autonomic Pharmacology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Coupland CA Hill T Dening T Morriss R Moore M Hippisley-Cox J Anticholinergic drug exposure and the risk of dementia: a nested case-control study JAMA Internal Medicine 2019 179 8 1084 93 31233095","DOI":"10.1001\/jamainternmed.2019.0677"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","article-title":"A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Djavan","year":"1999","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0075|cit75","unstructured":"EndNote Clarivate Analytics 2016"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.juro.2013.05.058","article-title":"The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis","volume":"190","author":"Filson","year":"2013","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD012336.pub2-BIB0077|cit77","first-page":"333","article-title":"Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications","volume":"108","author":"Fine","year":"2008","journal-title":"Journal of the American Osteopathic Association"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Fusco F Palmieri A Ficarra V Giannarini G Novara G Longo N Alpha1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies European Urology 2016 69 6 1091 101 26831507","DOI":"10.1016\/j.eururo.2015.12.034"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0080|cit80","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0081|cit81","unstructured":"Gravas S Bach T Bachmann A Drake M Gacci M Gratzke C Treatment of non-neurogenic male LUTS uroweb.org\/guideline\/treatment-of-non-neurogenic-male-luts\/"},{"issue":"7650","key":"10.1002\/14651858.CD012336.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD012336.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence \u2013 imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-410X.1995.tb07744.x","article-title":"Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia","volume":"76","author":"Hansen","year":"1995","journal-title":"British Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2004.04.005","article-title":"Lower urinary tract symptoms (LUTS) and sexual function in both sexes","volume":"46","author":"Hansen","year":"2004","journal-title":"European Urology"},{"issue":"7414","key":"10.1002\/14651858.CD012336.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0088|cit88","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0089|cit89","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0090|cit90","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"e0169248","DOI":"10.1371\/journal.pone.0169248","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis","volume":"12","author":"Kim","year":"2017","journal-title":"PloS One"},{"issue":"7","key":"10.1002\/14651858.CD012336.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1464-410X.2010.09274.x","article-title":"Benign prostatic hyperplasia: counting the cost of its management","volume":"105","author":"Kirby","year":"2010","journal-title":"BJU International"},{"issue":"9","key":"10.1002\/14651858.CD012336.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4111\/kju.2014.55.9.608","article-title":"Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin","volume":"55","author":"Ko","year":"2014","journal-title":"Korean Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bju.12802","article-title":"Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)","volume":"115","author":"Kozminski","year":"2015","journal-title":"BJU International"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0022-5347(17)47185-0","article-title":"A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra","volume":"134","author":"Kunisawa","year":"1985","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD012336.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.urology.2005.05.001","article-title":"Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects","volume":"66","author":"MacDonald","year":"2005","journal-title":"Urology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.juro.2009.06.051","article-title":"Do oral antimuscarinic drugs carry an increased risk of acute urinary retention?","volume":"182","author":"Martin-Merino","year":"2009","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0100|cit100","unstructured":"National Institute for Health and Care Excellence Lower urinary tract symptoms in men: management (Clinical Guideline 97) www.nice.org.uk\/guidance\/CG97"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bju.12906","article-title":"Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data","volume":"115","author":"Novara","year":"2015","journal-title":"BJU International"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2008.03.057","article-title":"Prevalence and characteristics of lower urinary tract symptoms in men aged \u2265 80 years","volume":"72","author":"Parsons","year":"2008","journal-title":"Urology"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0974-7753.188034","article-title":"An observational study of the association between androgenetic alopecia and size of the prostate","volume":"8","author":"Ramsamy","year":"2016","journal-title":"International Journal of Trichology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0105|cit105","unstructured":"Review Manager 5 (RevMan 5) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00042307-200401000-00003","article-title":"Does anticholinergic medication have a role for men with lower urinary tract symptoms\/benign prostatic hyperplasia either alone or in combination with other agents?","volume":"14","author":"Reynard","year":"2004","journal-title":"Current Opinion in Urology"},{"issue":"5","key":"10.1002\/14651858.CD012336.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urology.2008.06.067","article-title":"Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB","volume":"72","author":"Roehrborn","year":"2008","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0108|cit108","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ijcp.12044","article-title":"Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data","volume":"67","author":"Seftel","year":"2013","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD012336.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/02813432.2018.1487377","article-title":"Urological symptoms among 23,240 men in the general danish population \u2013 concerns about symptoms, their persistence and influence on primary care contacts","volume":"36","author":"Solvang","year":"2018","journal-title":"Scandinavian Journal of Primary Health Care"},{"issue":"9","key":"10.1002\/14651858.CD012336.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1345\/aph.1R282","article-title":"Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia","volume":"46","author":"Vande Griend","year":"2012","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.eururo.2005.09.016","article-title":"Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study","volume":"49","author":"Van Exel","year":"2006","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Wang YC Chen YL Huang CC Ho CH Huang YT Wu MP Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study BMC Geriatrics 2019 18 380 31888519","DOI":"10.1186\/s12877-019-1401-y"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/01.ju.0000155709.37840.fe","article-title":"Urologic diseases in America project: benign prostatic hyperplasia","volume":"173","author":"Wei","year":"2005","journal-title":"Journal of Urology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD012336.pub2-BIB0116|cit116","first-page":"S75","article-title":"Urologic diseases in America project: benign prostatic hyperplasia","volume":"179","author":"Wei","year":"2008","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012336.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/ciia.2006.1.4.389","article-title":"Doxazosin in the treatment of benign prostatic hypertrophy: an update","volume":"1","author":"Wilt","year":"2006","journal-title":"Clinical Interventions in Aging"},{"issue":"2","key":"10.1002\/14651858.CD012336.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2013.04.045","article-title":"Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis","volume":"82","author":"Xin","year":"2013","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD012336.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2011.02.055","article-title":"Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms \u2013 ASSIST, randomized controlled study","volume":"78","author":"Yamaguchi","year":"2011","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012336.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fphar.2020.00658","article-title":"Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia","volume":"11","author":"Yu","year":"2020","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012336.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"e022792","DOI":"10.1136\/bmjopen-2018-022792","article-title":"Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH) in China: results from the China Health and Retirement Longitudinal Study","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD012336.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4103\/0366-6999.154318","article-title":"Efficacy and safety of onabotulinumtoxin A in treating neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"128","author":"Zhou","year":"2015","journal-title":"Chinese Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD012336.pub2-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012336","article-title":"Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction","author":"Pang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:24:09Z","timestamp":1777911849000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012336.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012336.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]}}}